Comprehensive Review
Incidence of Lymphoma in Patients with Rheumatoid Arthritis: A Systematic Review of the Literature

https://doi.org/10.3816/CLM.2008.n.009Get rights and content

Abstract

To our knowledge, this review is the most broad and only systematic survey to date of the rheumatology, oncology, and epidemiology literature to determine the prevalence of lymphoma in patients with rheumatoid arthritis (RA). This survey is analyzed to determine whether the association between RA and increased lymphoma risk is a result of the risks conferred by medications used to treat RA or a result of the disease itself. PubMed was searched for articles from 1964 to May 2007 using the Medical Subject Heading terms “arthritis, rheumatoid, and lymphoma.” Twenty-six studies met inclusion and exclusion criteria and are included for review. Most studies confirmed an approximate 2-fold increase in lymphoma incidence in patients with RA. Contrary to a widely held belief about medication toxicity in RA, most studies did not reveal a statistically significant increased risk of lymphoma with methotrexate or azathioprine. An increased lymphoma incidence with tumor necrosis factor-α inhibitors was suggested; however, follow-up in the studies considered was too short to definitively determine increased risk. Most studies differed in which medications they evaluated in determining their impact on lymphoma risk, making studies difficult to compare. Confounding by disease severity (patients with the most severe disease are treated with the strongest medications) in most studies makes the association between lymphoma risk and medications and/or disease severity difficult to assess. Recent work suggests that it is the disease itself, not its treatment, that is associated with increased risk of lymphoma in patients with RA.

References (48)

  • G Gridley et al.

    Incidence of cancer among patients with rheumatoid arthritis

    J Natl Cancer Inst

    (1993)
  • E Baecklund et al.

    Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma

    Arthritis Rheum

    (2003)
  • E Thomas et al.

    Risk of malignancy among patients with rheumatic conditions

    Int J Cancer

    (2000)
  • GJ Goldenberg et al.

    The association of rheumatoid arthritis with plasma cell and lymphocytic neoplasms

    Arthritis Rheum

    (1969)
  • F Wolfe et al.

    Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

    Arthritis Rheum

    (2004)
  • National Cancer Institute

    Web site. Surveillance, Epidemiology, and End Results

  • E Baecklund et al.

    Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

    Arthritis Rheum

    (2006)
  • G Starkebaum

    Rheumatoid arthritis and lymphoma: risky business for B cells

    J Rheumatol

    (2007)
  • IR Mackay et al.

    Autoimmunity and lymphoma: tribulations of B cells

    Nat Immunol

    (2001)
  • KE Smedby et al.

    Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype

    J Natl Cancer Inst

    (2006)
  • FC Arnett et al.

    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

    Arthritis Rheum

    (1988)
  • M Egger

    Systematic Reviews in Health Care: Meta-Analysis in Context

    (2001)
  • J Franklin et al.

    Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community based prospective study

    Arthritis Rheum

    (2007)
  • EA Engels et al.

    Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study

    Am J Epidemiol

    (2005)
  • Cited by (45)

    • Autoimmunity, Clonal Hematopoiesis, and Myeloid Neoplasms

      2020, Rheumatic Disease Clinics of North America
    • B Lymphocytes in Rheumatoid Arthritis and the Effects of Anti–TNF-α Agents on B Lymphocytes: A Review of the Literature

      2018, Clinical Therapeutics
      Citation Excerpt :

      Patients treated with anti–tumor necrosis factor (TNF)-α, alone or with methotrexate (MTX), seem to be at further risk.6,7 Slightly elevated risks for lymphoma and lymphoproliferative malignant disease,8 lung cancer,9 or skin cancer10 have been associated with rheumatoid arthritis. Nonmelanoma skin cancer also appears to be increased in patients with rheumatoid arthritis in the setting of treatment with anti–TNF-α agents.10

    • Outcomes in Children Born to Women with Rheumatic Diseases

      2017, Rheumatic Disease Clinics of North America
      Citation Excerpt :

      Patients with SLE and RA have an increased risk of hematological malignancies, particularly non-Hodgkin lymphoma, compared with the general population.58 Large population-based studies have consistently shown more than a twofold increase in the risk of leukemia and lymphoma in SLE and RA, thought to be due to chronic immune stimulation.58 The most common type of hematological malignancy in SLE and RA is DLBCL.

    • Marginal zone lymphoma: Associated autoimmunity and auto-immune disorders

      2017, Best Practice and Research: Clinical Haematology
    View all citing articles on Scopus

    Electronic forwarding or copying is a violation of US and International Copyright Laws.

    Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1557-9190, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

    View full text